Assisted Reproduction Technology Unit, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
Department of Obstetrics & Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
Best Pract Res Clin Obstet Gynaecol. 2020 Oct;68:103-108. doi: 10.1016/j.bpobgyn.2020.02.013. Epub 2020 Mar 7.
Chronic Hepatitis B virus (HBV) infection is endemic worldwide, and the prevalence is especially high in the Asia-Pacific regions. Despite its high prevalence, the literature regarding the impact of HBV infection on subfertility and fertility treatment remains limited and conflicting. Latest studies do not suggest any detrimental effect of HBV infection on the outcome of IVF/ICSI treatment in women having chronic HBV infection. There is evidence that HBV exists in ovarian tissue including oocyte and follicular fluid, and therefore has the potential risk of transmission to the embryo, which can explain the finding of vertical transmission despite immunoprophylaxis. Most recently, we have observed the evidence of HBV viral replication in female HBV carriers undergoing IVF/ICSI treatment. This raises the question of whether antiviral medication should be administered during ovarian stimulation in IVF/ICSI treatment cycles for women with chronic HBV infection to help reduce the chance of vertical transmission.
慢性乙型肝炎病毒（HBV）感染在全球流行，在亚太地区尤为高发。尽管其发病率很高，但关于 HBV 感染对生育力和生育治疗影响的文献仍然有限且存在争议。最新研究表明，慢性 HBV 感染女性的 IVF/ICSI 治疗结局不受 HBV 感染的不利影响。有证据表明 HBV 存在于卵巢组织中，包括卵母细胞和卵泡液，因此有传播给胚胎的潜在风险，这可以解释尽管进行了免疫预防，但仍存在垂直传播的发现。最近，我们观察到在接受 IVF/ICSI 治疗的女性 HBV 携带者中存在 HBV 病毒复制的证据。这就提出了一个问题，即在慢性 HBV 感染女性的 IVF/ICSI 治疗周期中，卵巢刺激期间是否应该给予抗病毒药物，以帮助降低垂直传播的机会。
